Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Insmed Chief Argues For Five-Year Biologics Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.

You may also be interested in...

Insmed’s Biogeneric Deemed Equal To Neupogen

Despite regulatory murkiness, firm will forge ahead with new Phase III trial, CEO says.

Insmed Takes Follow-On Biologics Push To The Web

Not enough understanding of debate, says Insmed exec; economic study to come

New York State To Conduct Its Own Review Of COVID-19 Vaccines In Another Blow To FDA’s Reputation

Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts